Study S003385

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06885021
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 780
Start: 2025-03-28
Primary completion: 2026-05-30
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Overweight and Obesity
Interventions: DRUG:HDM1002 200mg, oral, once daily, 52 weeks; DRUG:HDM1002 400mg, oral, once daily, 52 weeks; DRUG:HDM1002 placebo, oral, once daily, 52 weeks
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Percentage Change From Baseline in Body Weight [44weeks]
Percentage Change of Participants Achieving Weight Loss ≥ 5% [44weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.